8chan/8kun QResearch Posts (9)
#20565305 at 2024-03-14 09:18:09 (UTC+1)
Q Research General #25223: Why is California still building the high-speed train? Edition
They're vaccinating children in Africa (again)
This time for malaria (could've sworn there was already a cheap, proven drug for that… strange)
https://medicalxpress.com/news/2024-02-high-efficacy-good-safety-profile.html
Feb 2, 2024
High efficacy and good safety profile for the R21/Matrix-M malaria vaccine in African children
by University of Oxford
Kaplan-Meier estimates of the time to first episode of clinical malaria in the modified per-protocol population at seasonal sites (A), standard sites (B), and all sites (C). Credit: The Lancet (2024). DOI: 10.1016/S0140-6736(23)02511-4
Phase III trial results of the R21/Matrix-M vaccine developed by Oxford University and Serum Institute of India Pvt Ltd, leveraging Novavax's Matrix-M adjuvant, has confirmed high efficacy and supported regulatory approvals and licensure in several African countries.
The R21/Matrix-M vaccine was designed in 2011 as a potential improvement on the RTS, S/AS01 malaria vaccine designed in the 1980s. A Phase II trial in Burkina Faso, reporting in 2021, was the first to show that R21/Matrix-M could reach the WHO-specified target of 75% efficacy in African children.
Recent WHO endorsement will lead to the initial rollout of R21/Matrix-M in the coming months. The new results are published in The Lancet.
The trial investigators immunized over 4,800 young children in a trial in Burkina Faso, Kenya, Mali and Tanzania and found on average 78% vaccine efficacy over the first year of follow-up across all sites in the 5-17 month age group, the age range group which is studied for most malaria vaccines.
Efficacy over this period was broadly similar across sites and in different transmission settings. Safety data from the trial have been reassuring with no serious adverse events linked to immunization. No other vaccine has reported over 55% efficacy in the same age group.
A booster dose at a year maintained good efficacy over the following 6-12 months. The vaccine also reduced infection rates in children measured at 12 and 18 months after vaccination suggesting a potentially beneficial effect in reducing malaria transmission.
(body too long, some omitted)
(body too long, some omitted)
Professor Adrian Hill, chief investigator of the R21/Matrix-M Phase III trial said "The continued high efficacy of this new vaccine in field trials is very encouraging, and consistent with the high efficacy and excellent durability observed in a smaller four-year Phase IIb trial. These data support an important role for the unique high-density nanoparticle display of the conserved repeat region of the malaria parasite circumsporozoite protein, a feature in the design of the R21 vaccine, in providing such high vaccine efficacy and, thereby, an important new tool for malaria control."
Significantly increased immune responses to the R21/Matrix-M vaccine and slightly higher vaccine efficacy were observed in 5- to 17-month-olds compared to 18- to 36-month-olds malaria vaccines, supporting planned vaccine deployment initially from 5 months of age in young African children.
The vaccine is licensed to the Serum Institute of India (SII), the world's largest vaccine manufacturer and a long-term partner of the University of Oxford. This is critical because vaccinating those at high risk of malaria will be important in stemming the spread of the disease, as well as protecting the vaccinated. Matrix-M adjuvant is manufactured by Novavax AB and provided to Serum Institute of India for formulation into the final vaccine drug product.
Adar Poonawalla, CEO, Serum Institute of India, said, "The Lancet study on R21/Matrix-M Phase III trials mark a significant advancement in our battle against this global threat. Our collaboration with the University of Oxford has been instrumental in developing the R21/Matrix-M malaria vaccine. We are dedicated to making this vaccine available, especially in Africa, where malaria poses a substantial threat to millions of lives, bringing us closer to a malaria-free world."
Professor Alassane Dicko, Principal Investigator in Mali of the R21/Matrix-M vaccine said "It has been very exciting to generate high efficacy data with the new R21/Matrix-M vaccine so quickly. I predict that this vaccine should be very impactful in preventing malaria deaths in African children."
John C Jacobs, CEO of Novavax commented "Approximately 1,300 children die from malaria every day, a staggering statistic for a preventable disease. The R21/Matrix-M Phase III efficacy data published in The Lancet reinforce the potential of R21/Matrix-M vaccine to protect children against this disease."
#18689495 at 2023-04-13 19:02:04 (UTC+1)
Q Research General #22929: Misneach calls Biden's BS #Dogcomms Edition
African nation becomes first to approve new vaccine
Ghana has given clearance for an anti-malaria serum developed by Oxford University
Ghana has given regulatory clearance to a new malaria vaccine developed by Oxford University scientists. The West African country is the first in the world to approve the use of the R21/Matrix-MTM serum, the university said on Thursday.
The vaccine has been endorsed by Ghana's drug regulator, the Food and Drugs Authority, "for use in children aged five to 36 months, the age group at the highest risk of death from malaria."
Severe Malaria Observatory data has shown that Ghana is one of the 15 countries with the highest malaria burden in the world, accounting for 4.3% of cases in West Africa. In 2021, it was estimated by the World Health Organization (WHO) that the country recorded over 5 million cases of malaria and more than 12,000 fatalities as a result.
The approval of the Oxford malaria vaccine, which was manufactured using Novavax's adjuvant technology, has been hailed as a significant step forward in the global fight against the mosquito-borne disease.
"This marks a culmination of 30 years of malaria vaccine research at Oxford," said Adrian Hill, chief investigator of the R21/Matrix-M program, as he applauded clinical trial partners in Africa.
Hill noted the vaccine has a production agreement with the Serum Institute of India for up to 200 million doses per year, and that the WHO is still evaluating its safety and effectiveness. The Oxford scientist stated that African regulators have become more proactive, recognizing the importance of prioritizing public health in their respective countries.
According to Oxford University, the low cost and high scalability of the "low-dose" R21/Matrix-M vaccine make it a viable option for mass production and distribution to African nations grappling with the devastating impact of malaria. Clinical trials for the vaccine have reportedly taken place in the UK, Thailand, and several African countries, including a 4,800-child phase III trial in Burkina Faso, Kenya, Mali, and Tanzania.14:41
https://www.rt.com/africa/574678-ghana-approves-oxford-malaria-vaccine/
#17902946 at 2022-12-07 19:01:23 (UTC+1)
Q Research General #21939: 81st anniversary of the attack on #PearlHarbor Edition
>>17902943
In 1998, Anderson would again become a government advisor and he would soon have his attention diverted towards a new variant of Bovine Spongiform Encephalopathy (BSE), a progressive neurological disorder of cattle, which is commonly referred to as Mad Cow's Disease. Some cattle in Britain during this era were being fed a meat-and-bone meal that included the remains of other potentially affected cattle. One of the main issues was that it took four to five years to show up in the affected cows. This meant that by the time the cause was identified and rectified, the damage had already been done.
BSE had been discovered in 1985 by a junior pathologist who identified a spongy brain disease in a Frisian cow, but the connection with a potentially new form of bovine encephalopathy had not been recognised by senior officials until 1987. In 1996, the UK Government was advised that a new variant had been identified in humans and later, in December 1997, it was announced that there would be an inquiry into the history and emergence of BSE, and the Government's response to the crisis up until March 1996. The Inquiry, which would produce Roy Anderson as a key witness, started on 12 January 1998.
The BSE scandal was a well managed affair, it needed to be as the conservative government of the day had found themselves in a bit of hot water. During the period of 1983 until 1991, Sir Donald Acheson had been the government's Chief Medical Officer and had downplayed the risk of the potential cross-species spread of the illness. A cat had been diagnosed with the illness and, even with an example of cross species transmission of the disease, he had continuously recommended that it was safe to eat meat contaminated with BSE, stating clearly in 1990: "British beef can be eaten safely by everyone". Acheson wasn't the only representative of a scientific entity at the time to be more concerned with sales of meat and milk than human health. The Southwood Working Party, which was led by Erik Millstone and a man named Patrick van Zwanenberg, would also claim in the early 90s that the offal of infected cattle was "safe for adults but not for babies". The disease would eventually be transmitted to humans from the eating of contaminated beef. The official BSE inquiry would mostly attempt to shift the blame for the poorly managed response away from the government and on to the early stooges who had been tasked with playing down the risks. This moment was important in Anderson's development. His usefulness in managing the narrative of a precarious public inquiry had been noted by the Establishment and he would henceforth become a useful tool in the governments toolbox.
By the late 90s, Anderson's prestigious career had also seen him daubed with various honorary positions, titles and memberships, including his fellowship at the very exclusive Royal Society and the Zoological Society, as well as being a board member on many various international advisory panels. Some of these positions would be jeopardised by his own behaviour. In 1999, Anderson was suspended from his position at Oxford after he stated that a colleague of his had only got her promotion by sleeping around. The person he was targetting was Dr Sunetra Gupta, who would over two decades later oppose Anderson's extreme lockdown tactics during the Covid crisis as a signatory of the Great Barrington Declaration. Notably, Gupta was married to Adrian Hill at this time, the man who has affiliations to the Wellcome Trust and who would later co-head the creation of the Oxford AZ vaccine during Covid-19, alongside Sarah Gilbert. At first, Anderson refused to retract his statements about Gupta, or apologise in any form, but eventually he was allowed to return to his Oxford position under the condition that he write a private apology to the people he had slandered. Anderson may have agreed to this proverbial slap on the wrists by the Oxford authorities, but Dr Gupta did not see this as an acceptable outcome. She demanded that he publicly retract his statement and that he also pay her a small amount of damages which would go to a charity. The pathetic drama, all to protect the ego of a misogynistic elite scientist, did not lead to Anderson retaining his position. A vote of no confidence from the board at Oxford would be unanimous, infuriating Anderson.
p7
#13793359 at 2021-05-30 18:51:41 (UTC+1)
Q Research General #17461: Ghost Bake, Are We There Yet?
Developers of Oxford-AstraZeneca Vaccine Tied to UK Eugenics Movement
By JEREMY LOFFREDO | WHITNEY WEBB
The developers of the Oxford-AstraZeneca vaccine have previously undisclosed ties to the re-named British Eugenics Society as well as other Eugenics-linked institutions like the Wellcome Trust.
AstraZeneca and the University of Oxford announced a "landmark agreement" for the development of a COVID-19 vaccine. The agreement involves AstraZeneca overseeing aspects of the development as well as manufacturing and distribution while the Oxford side, via the Jenner Institute and Oxford Vaccine Group, researched and developed the vaccine. Less than a month after this agreement was reached, the Oxford-AstraZeneca partnership was awarded a contract from the US government as part of Operation Warp Speed, the public-private COVID-19 vaccination effort dominated by the US military and US intelligence.
Though the partnership was announced in April, Oxford's Jenner Institute had already begun developing the COVID-19 vaccine months before, in mid-January. According to a recent BBC report, it was in January that the Jenner Institute first became aware of how serious the pandemic would soon become, when Andrew Pollard, who works for the Jenner Institute and heads the Oxford Vaccine Group, "shared a taxi with a modeler who worked for the UK's Scientific Advisory Group for Emergencies." During the taxi ride, "the scientist told him data suggested there was going to be a pandemic not unlike the 1918 flu." Because of this sole encounter, we are told, the Jenner Institute began to pour millions into the early development of a vaccine for COVID-19, well before the scope of the crisis was clear.
For much of 2020, the Oxford-AstraZeneca vaccine was treated as an early frontrunner, though its lead would later be marred by scandals related to its clinical trials, including the death of participants, sudden trial pauses, the use of a problematic "placebo" with its own host of side effects, and the "unintentional" misdosing of some participants that skewed its self-reported efficacy rate.
The significant issues that emerged during trials have provoked little concern from the vaccine's two lead developers, despite critical attention from even mainstream media directed at its complications. The lead developer of the Oxford-AstraZeneca vaccine, Adrian Hill, told NBC on December 9 that the experimental vaccine should be approved and distributed to the public before the conclusion of the safety trials, saying "to wait for the end of the trial would be the middle of next year. That's too late, this vaccine is effective, available at large scale and easily deployed."
Sarah Gilbert, the other lead researcher on the vaccine, seemed to believe that premature safety approval was likely, telling the BBC on December 13 that the chances of rolling out the vaccine by the end of the year are "pretty high." Now, the UK is expected to approve the Oxford-AstraZeneca vaccine shortly after Christmas, with India also set to approve the vaccine next week.
While the controversies surrounding the vaccine's trials did ultimately undermine its previous frontrunner status, the Oxford-AstraZeneca vaccine remains heavily promoted as the vaccine of choice for the developing world, as it is cheaper and has much less complicated storage requirements than its main competitors, Pfizer and Moderna.
Earlier this month, Richard Horton, editor in chief of the Lancet medical journal, told CNBC that "the Oxford-AstraZeneca vaccine is the vaccine right now that is going to be able to immunize the planet more effectively, more rapidly than any other vaccine we have," in large part because it is a "vaccine that can get to lower-middle-income countries." CNBC also quoted Andrew Baum, global head of health care for Citi Group, as saying that the Oxford-AstraZeneca vaccine "is really the only vaccine that is going to suppress or even eradicate SARS-CoV-2, the virus that causes COVID-19, in the many millions of individuals in the developing world."
much moar @
https://australiannationalreview.com/health/developers-of-oxford-astrazeneca-vaccine-tied-to-uk-eugenics-movement/
https://archive.is/wip/dKKb7
#13494145 at 2021-04-23 13:14:53 (UTC+1)
Q Research General #17092: What is SpaceX? Expand your thinking.
'Game-changing' malaria vaccine is 77% effective at stopping infection
A malaria vaccine from the Oxford institute behind the coronavirus jab is 77 per cent effective at stopping infection, in results that suggest it could be a game changer in defeating the illness.
The new study, from clinical trials of 450 children, is published as the vaccine enters larger-scale human trials to test for rarer side-effects.
If safety is assured, health authorities say that it will become the key weapon in eliminating the disease, which is responsible for half a million deaths a year, mostly in children.
Adrian Hill, director of the Jenner Institute in Oxford, said that the results were thrilling. Despite decades of research there is only one other vaccine against malaria and it is about 36 per cent effective.
Hill said it was imperative that regulators treated the vaccine with the same urgency as those against Covid-19. "Malaria is a public health emergency. More people died from malaria last year in Africa than Covid by a factor of at least four," he said.
moar: https://www.thetimes.co.uk/article/965ba060-a39a-11eb-949b-ab1b919d4f89
#12147786 at 2020-12-23 18:46:24 (UTC+1)
Q Research General #15510: One Man With Courage Makes A Majority Edition
Another Flawed Data Model from Imperial College to Blame for Latest UK Lockdown
The source behind the claim that a new COVID-19 strain in the UK is 70% more transmissible, Dr. Erik Volz of Imperial College, admits that the model that produced that statistic is flawed and that it is "too early to tell" if the strain is more easily spread.
On Saturday, UK Prime Minister Boris Johnson announced extreme new measures just before the holidays due to the emergence of a new COVID-19 variant. Per Johnson, as well as the UK's Chief Medical Officer Chris Whitty who also spoke at Saturday's press conference, the new strain - nicknamed VUI-202012/01- is around 70% more transmissible, but no evidence shows it to be any more severe or deadly than previous strains.
According to the BBC, Johnson's assertion that the new variant "may be up to 70% more transmissible," was based on the information discussed the day prior by the UK government's New and Emerging Respiratory Virus Threats Advisory Group, or NERVTAG. Yet, as the BBC notes, this figure apparently comes from a single source, a 10 minute presentation delivered by Dr. Erik Volz of Imperial College given last Friday, the same day as the NERVTAG meeting.
Volz - a close colleague of the discredited Neil Ferguson - delivered the presentation to COVID-19 Genomics UK (COG-UK), a research consortium largely funded by the UK government and the Wellcome Trust and, in particular, the Wellcome Sanger Institute. The Wellcome Sanger Institute recently came under fire for "misusing" the DNA of Africans to develop a "gene chip without proper legal agreements" and an upcoming Unlimited Hangout report will detail the ties of the Wellcome Trust to the UK eugenics movement, the Bill and Melinda Gates Foundation and the Oxford-AstraZeneca COVID-19 vaccine. Notably, the Wellcome-funded scientist behind that vaccine candidate, Adrian Hill, was recently quoted by the Washington Post as saying that "We're in the bizarre position of wanting COVID to stay, at least for a little while...But cases are declining." The UK government, Google and other powerful stakeholders are positioned to profit from sales of that particular vaccine candidate.
According to Volz's most recent publication, COG-UK "has resulted in the generation of >40,000 SARS-CoV-2 sequences from the country in <6 months (approximately half of all genomes sequenced globally as of 7 July)" and "has facilitated the usage of robust and systematic sampling and shared bioinformatic and laboratory approaches and the collection of consistent core metadata, resulting in a large, high-resolution dataset capable of examining changes in virus biology in the United Kingdom."
https://www.naturalblaze.com/2020/12/another-flawed-data-model-from-imperial-college-to-blame-for-latest-uk-lockdown.html
#9328874 at 2020-05-27 07:15:06 (UTC+1)
Q Research General #11939: The WAR Edition
Vaccine Development Threatened as COVID-19 Infections Decline
(new fear porn - Covid-19 disappearing too quickly) - KEK!
"However, Oxford researchers are now warning of an obstacle in the trial process. As new cases of COVID-19 are declining, they worry the data will not meet the hurdles to prove effectiveness. They are now placing the odds of a successful trial at 50%. Professor Adrian Hill is sounding the alarm:
The stakes could hardly be higher. If proven effective, the ZD1222 vaccine would allow people to leave their homes and go back to work, and the shattered global economy to rebuild. But Hill, director of the university's Jenner Institute, revealed his team now faced a major problem, throwing the September deadline into doubt.
"It is a race, yes. But it's not a race against the other guys. It's a race against the virus disappearing, and against time," he said. "At the moment, there's a 50 per cent chance that we get no result at all."
https://pjmedia.com/news-and-politics/stacey-lennox/2020/05/26/vaccine-development-threatened-as-covid-19-infections-decline-n428072
#9299184 at 2020-05-24 18:20:43 (UTC+1)
Q Research General #11901: WWG1WGA, WW WRWY Edition
Hotly-touted Oxford coronavirus VACCINE trial has only 50 percent chance of success, project leader warns
The professor leading Oxford University's highly-anticipated coronavirus vaccine trial has poured cold water on much of the hype surrounding the project by warning that it has only a 50 percent chance of being successful.
In an interview in the Telegraph on Sunday, Professor Adrian Hill, director of Oxford's Jenner Institute, said that the upcoming trial, involving 10,000 volunteers, threatens to return "no result" due to low transmission of Covid-19 in the community.
While the low incidence of the virus among the public is undoubtedly positive news, it leaves vaccine-makers with a major problem, as without Covid-19 circulating volunteers will not catch the illness and scientists won't be able to prove that their vaccine works.
"It's a race against the virus disappearing, and against time," the expert told the British newspaper.
At the moment, there's a 50 percent chance that we get no result at all.
Oxford University has teamed up with drugmaker AstraZeneca Plc to develop the experimental vaccine, known as ChAdOx1 nCoV-19, which is one of the leading candidates in the global race for protection against the coronavirus responsible for the Covid-19 pandemic.
https://www.rt.com/uk/489606-oxford-coronavirus-vaccine-50-percent-chance-success/
Moderna fail last week Oxford fail this week?
#9297888 at 2020-05-24 15:42:03 (UTC+1)
Q Research General #11899: The 'Voter Fraud Is Un-American.' Edition
UK COVID-19 vaccine trial may fail due to low transmission in population
There is a 50% chance the trial may give 'no result.'
Hopes that a vaccine for the coronavirus could be ready by September are hanging in the balance, as the scientists developing it are concerned that a slowdown in the rate of infection in the general population could invalidate the human trials currently taking place.
Prof. Adrian Hill, Director of the Oxford University's Jenner Institute, has told The Telegraph that there is only a 50-50 chance that the vaccine his team has been developing can be successfully tested.
https://www.jpost.com/international/uk-covid-19-vaccine-trial-may-fail-due-to-low-transmission-in-population-629082
8chan/8kun QRB Posts (1)
#58282 at 2021-05-30 20:17:16 (UTC+1)
QRB General #245: Remember 45! Edition
Developers of Oxford-AstraZeneca Vaccine Tied to UK Eugenics Movement
By JEREMY LOFFREDO | WHITNEY WEBB
The developers of the Oxford-AstraZeneca vaccine have previously undisclosed ties to the re-named British Eugenics Society as well as other Eugenics-linked institutions like the Wellcome Trust.
AstraZeneca and the University of Oxford announced a "landmark agreement" for the development of a COVID-19 vaccine. The agreement involves AstraZeneca overseeing aspects of the development as well as manufacturing and distribution while the Oxford side, via the Jenner Institute and Oxford Vaccine Group, researched and developed the vaccine. Less than a month after this agreement was reached, the Oxford-AstraZeneca partnership was awarded a contract from the US government as part of Operation Warp Speed, the public-private COVID-19 vaccination effort dominated by the US military and US intelligence.
Though the partnership was announced in April, Oxford's Jenner Institute had already begun developing the COVID-19 vaccine months before, in mid-January. According to a recent BBC report, it was in January that the Jenner Institute first became aware of how serious the pandemic would soon become, when Andrew Pollard, who works for the Jenner Institute and heads the Oxford Vaccine Group, "shared a taxi with a modeler who worked for the UK's Scientific Advisory Group for Emergencies." During the taxi ride, "the scientist told him data suggested there was going to be a pandemic not unlike the 1918 flu." Because of this sole encounter, we are told, the Jenner Institute began to pour millions into the early development of a vaccine for COVID-19, well before the scope of the crisis was clear.
For much of 2020, the Oxford-AstraZeneca vaccine was treated as an early frontrunner, though its lead would later be marred by scandals related to its clinical trials, including the death of participants, sudden trial pauses, the use of a problematic "placebo" with its own host of side effects, and the "unintentional" misdosing of some participants that skewed its self-reported efficacy rate.
The significant issues that emerged during trials have provoked little concern from the vaccine's two lead developers, despite critical attention from even mainstream media directed at its complications. The lead developer of the Oxford-AstraZeneca vaccine, Adrian Hill, told NBC on December 9 that the experimental vaccine should be approved and distributed to the public before the conclusion of the safety trials, saying "to wait for the end of the trial would be the middle of next year. That's too late, this vaccine is effective, available at large scale and easily deployed."
Sarah Gilbert, the other lead researcher on the vaccine, seemed to believe that premature safety approval was likely, telling the BBC on December 13 that the chances of rolling out the vaccine by the end of the year are "pretty high." Now, the UK is expected to approve the Oxford-AstraZeneca vaccine shortly after Christmas, with India also set to approve the vaccine next week.
While the controversies surrounding the vaccine's trials did ultimately undermine its previous frontrunner status, the Oxford-AstraZeneca vaccine remains heavily promoted as the vaccine of choice for the developing world, as it is cheaper and has much less complicated storage requirements than its main competitors, Pfizer and Moderna.
Earlier this month, Richard Horton, editor in chief of the Lancet medical journal, told CNBC that "the Oxford-AstraZeneca vaccine is the vaccine right now that is going to be able to immunize the planet more effectively, more rapidly than any other vaccine we have," in large part because it is a "vaccine that can get to lower-middle-income countries." CNBC also quoted Andrew Baum, global head of health care for Citi Group, as saying that the Oxford-AstraZeneca vaccine "is really the only vaccine that is going to suppress or even eradicate SARS-CoV-2, the virus that causes COVID-19, in the many millions of individuals in the developing world."
much moar @
https://australiannationalreview.com/health/developers-of-oxford-astrazeneca-vaccine-tied-to-uk-eugenics-movement/
https://archive.is/wip/dKKb7
8chan/8kun QResearch AUSTRALIA Posts (1)
#10315234 at 2020-08-17 06:28:09 (UTC+1)
Q Research AUSTRALIA #9 - Welcome to the Digital Battlefield Edition
Australia could have a COVID-19 vaccine within six months
Australia could have access to a vaccine for COVID-19 within six months and negotiations are already under way to secure the jab, the Health Minister says.
Australians could have access to a vaccine against the deadly coronavirus within six months, Health Minister Greg Hunt says.
The Government is in negotiations with a number of companies to procure the University of Oxford's vaccine candidate, which is still being tested but has shown promising results.
Mr Hunt called it a "ray of hope" that Australia could be able to vaccinate against the virus by early next year.
"I am now, on the basis of our best medical advice, more optimistic," he told Sky News on Sunday.
"I think the world is moving closer to a vaccine … If anything occurs before then that would be an outstanding result, not just for Australia, but the world.
"For the first time, I feel cautiously but genuinely optimistic about the prospect of a vaccine."
It is understood that one of the companies Australia is negotiating with is British pharmaceutical giant AstraZeneca.
It comes after researchers from Oxford University revealed positive results from trials on their vaccine last month.
Research published in the journal Lancet claims an experimental vaccine - labelled ChAdOx1 nCoV-19 - was tested on more than 1000 people and prompted a protective immune response in those aged 18 to 55.
"The vaccine was safe and tolerated," researchers wrote.
"Preliminary results from a phase 1/2 trial involving 1077 healthy adults found that vaccine induced strong antibody & T cell immune responses up to day 56 of the ongoing trial," the Lancet wrote when announcing the breakthrough on social media on Monday night.
"These responses may be even greater after a 2nd dose, according to a subgroup study of 10 participants."
Oxford University's Jenner Institute director Dr Adrian Hill, said the results were hugely promising.
"We are seeing good immune response in almost everybody," Dr Hill told the Associated Press.
"What this vaccine does particularly well is trigger both arms of the immune system."
He claimed the vaccine causes a reaction in the body's T-cells which help to fight off the coronavirus and that a partnership was already underway with a drug manufacturer to produce millions of doses.
https://www.news.com.au/lifestyle/health/health-problems/australia-could-have-a-covid19-vaccine-within-six-months/news-story/6e755868b561e800d90e60f224783037